Profil
Erik Buntinx was the founder and had founded PharmaNeuroBoost NV in 2006, where he held the titles of CEO, Director, Chief Scientific Officer & MD from 2012 to 2013.
Currently, he is the Chief Executive Officer & Chief Scientific Officer at ANeuroTech BV.
Dr. Buntinx has an undergraduate degree from Maastricht University and a doctorate degree from Université Catholique de Louvain.
Postes actifs de Erik Buntinx
| Sociétés | Poste | Début |
|---|---|---|
ANeuroTech
 ANeuroTech Miscellaneous Commercial ServicesCommercial Services ANeuroTech is a Belgian mental health company that specializes in developing innovative treatments with minimal or no side effects. ANeuroTech is located in Belgium. The private company's lead asset, ant-01, is an adjunctive anti-depression drug that has shown positive results in late-stage clinical trials. The drug is a low-dose of an existing substance, pipamperone dihydrochloride, and has an excellent safety profile. ANeuroTech plans to begin a pivotal phase iiib clinical trial of ant-01 as an adjunctive anti-depression drug for major depressive disorder (MDD) in 2023. The company was founded by CEO Dr. Erik Buntinx, an experienced clinician and key opinion leader in the field. | Directeur Général | - |
Anciens postes connus de Erik Buntinx
| Sociétés | Poste | Fin |
|---|---|---|
PharmaNeuroBoost NV
 PharmaNeuroBoost NV Miscellaneous Commercial ServicesCommercial Services PharmaNeuroBoost NV operates as a drug development company for psychiatric disorders. The company was founded in 2006 and it is headquartered in Alken, Belgium | Directeur Général | 05/12/2013 |
Formation de Erik Buntinx
| Maastricht University | Undergraduate Degree |
| Université Catholique de Louvain | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
PharmaNeuroBoost NV
PharmaNeuroBoost NV Miscellaneous Commercial ServicesCommercial Services PharmaNeuroBoost NV operates as a drug development company for psychiatric disorders. The company was founded in 2006 and it is headquartered in Alken, Belgium | Commercial Services |
ANeuroTech
ANeuroTech Miscellaneous Commercial ServicesCommercial Services ANeuroTech is a Belgian mental health company that specializes in developing innovative treatments with minimal or no side effects. ANeuroTech is located in Belgium. The private company's lead asset, ant-01, is an adjunctive anti-depression drug that has shown positive results in late-stage clinical trials. The drug is a low-dose of an existing substance, pipamperone dihydrochloride, and has an excellent safety profile. ANeuroTech plans to begin a pivotal phase iiib clinical trial of ant-01 as an adjunctive anti-depression drug for major depressive disorder (MDD) in 2023. The company was founded by CEO Dr. Erik Buntinx, an experienced clinician and key opinion leader in the field. | Commercial Services |
